GI Innovation, Inc. (KOSDAQ:358570)

South Korea · Delayed Price · Currency is KRW

6,810.00

+80.00 (1.19%)

Nov 2, 2026, 3:30 PM KST

Market Cap	439.35B -54.4%
Revenue (ttm)	5.50B +1,526.8%
Net Income	-39.14B
EPS	-614.06
Shares Out	64.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,206
Open	6,700.00
Previous Close	6,730.00
Day's Range	6,550.00 - 6,880.00
52-Week Range	6,470.00 - 20,950.00
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 358570

Full Company Profile

Financial Performance

In 2025, GI Innovation's revenue was 5.84 billion, an increase of 23943.39% compared to the previous year's 24.28 million. Losses were -35.13 billion, -40.23% less than in 2024.

Financial Statements